��ɫ��

��ɫ��

Events

Resources For

Abstract Details

Title Clinical Features of the Schwannomatosis Tumor Suppressor Syndrome: A Retrospective Analysis of 87 Patients

Topic Neuro-oncology

Presentation(s) (-)

Poster/Presentation
Number 003

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Vanessa Merker (Massachusetts General Hospital)	The institution of Vanessa Merker has received research support from Children's Tumor Foundation . The institution of Vanessa Merker has received research support from NF Northeast. The institution of Vanessa Merker has received research support from Patient Centered Outcomes Research Institute. The institution of Vanessa Merker has received research support from U.S. Department of Defense . The institution of Vanessa Merker has received research support from Neurofibromatosis Therapeutic Accleration Project. Vanessa Merker has received personal compensation in the range of $10,000-$49,999 for serving as a Science Writer with Neurofibromatosis Network.
	No disclosure on file
Analia Calle	Analia Calle has nothing to disclose.
Miriam R. Smith	No disclosure on file
David J. Dickoff, MD	No disclosure on file
	No disclosure on file
Scott R. Plotkin, MD, PhD, FAAN (Mass General Cancer Center)	Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NFlection Therapeutics. Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Akouos. Dr. Plotkin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SonALAsense. Dr. Plotkin has stock in NFlection Therapeutics. Dr. Plotkin has stock in NF2 Therapeutics. Dr. Plotkin has stock in SonALAsense. Dr. Plotkin has received research support from Children's Tumor Foundation. Dr. Plotkin has received research support from Department of Defense. Dr. Plotkin has received research support from National Institutes of Health. Dr. Plotkin has received intellectual property interests from a discovery or technology relating to health care.